Bayer Starts Phase III Clinical Development Program OASIS With Investigational Product, Elinzanetant
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer, a global leader in women’s healthcare, announced today that it started the Phase III clinical development program OASIS, which aims to evaluate the efficacy and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results